Phase II trial of volasertib (BI 6727) versus chemotherapy (CT) in platinum-resistant/refractory ovarian cancer (OC)

被引：0
|
作者：
Pujade-Lauraine, Eric
Weber, Beatrice E.
Ray-Coquard, Isabelle
Vergote, Ignace
Selle, Frederic
Del Campo, Jose Maria
Sufliarsky, Jozef
Tschoepe, Inga
Chesa, Pilar Garin
Nazabadioko, Serge
Pilz, Korinna
Joly, Florence
机构：
[1] Hop Hotel Dieu, AP HP, Unite Oncol Med, F-75181 Paris, France
[2] Ctr Alexis Vautrin, Vandoeuvre Les Nancy, France
[3] Ctr Leon Berard, F-69373 Lyon, France
[4] Katholieke Univ Leuven, Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium
[5] Katholieke Univ Leuven, Univ Hosp Leuven, Leuven, Belgium
[6] Hop Tenon, F-75970 Paris, France
[7] Vall dHebron Inst Oncol, Barcelona, Spain
[8] Natl Canc Inst, Bratislava, Slovakia
[9] Boehringer Ingelheim GmbH & Co KG, Reims, France
[10] Boehringer Ingelheim GmbH & Co KG, Vienna, Austria
[11] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany
[12] Ctr Francois Baclesse, F-14021 Caen, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5504
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
    Oza, Amit M.
    Matulonis, Ursula A.
    Secord, Angeles Alvarez
    Nemunaitis, John
    Roman, Lynda D.
    Blagden, Sarah P.
    Banerjee, Susana
    McGuire, William P.
    Ghamande, Sharad
    Birrer, Michael J.
    Fleming, Gini F.
    Markham, Merry Jennifer
    Hirte, Hal W.
    Provencher, Diane M.
    Basu, Bristi
    Kristeleit, Rebecca
    Armstrong, Deborah K.
    Schwartz, Benjamin
    Braly, Patricia
    Hall, Geoff D.
    Nephew, Kenneth P.
    Jueliger, Simone
    Oganesian, Aram
    Naim, Sue
    Hao, Yong
    Keer, Harold
    Azab, Mohammad
    Matei, Daniela
    CLINICAL CANCER RESEARCH, 2020, 26 (05) : 1009 - 1016
  • [32] Preliminary results of a phase II study of gemcitabine and epirubicin in platinum-resistant or refractory advanced ovarian cancer.
    Arcuri, C
    Sorio, R
    Caffo, O
    Scalone, S
    Griso, C
    Lucenti, A
    Valdurga, F
    Frisinghelli, M
    Arisi, E
    Galligioni, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 472S - 472S
  • [33] Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer - A Gynecologic Oncology Group study
    Plaxe, SC
    Blessing, JA
    Morgan, MA
    Carlson, J
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (01): : 45 - 47
  • [34] Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
    Moore, K. N.
    Oza, A. M.
    Colombo, N.
    Oaknin, A.
    Scambia, G.
    Lorusso, D.
    Konecny, G. E.
    Banerjee, S.
    Murphy, C. G.
    Tanyi, J. L.
    Hirte, H.
    Konner, J. A.
    Lim, P. C.
    Prasad-Hayes, M.
    Monk, B. J.
    Pautier, P.
    Wang, J.
    Berkenblit, A.
    Vergote, I
    Birrer, M. J.
    ANNALS OF ONCOLOGY, 2021, 32 (06) : 757 - 765
  • [35] Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6)
    Kiyoshi Yoshino
    Shoji Kamiura
    Takeshi Yokoi
    Ruriko Nakae
    Masami Fujita
    Masahiko Takemura
    Kazushige Adachi
    Akinori Wakimoto
    Takamichi Nishizaki
    Yasuhiko Shiki
    Tateki Tsutsui
    Yuki Kanda
    Eiji Kobayashi
    Kae Hashimoto
    Seiji Mabuchi
    Yutaka Ueda
    Kenjiro Sawada
    Takuji Tomimatsu
    Tadashi Kimura
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 1239 - 1247
  • [36] Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6)
    Yoshino, Kiyoshi
    Kamiura, Shoji
    Yokoi, Takeshi
    Nakae, Ruriko
    Fujita, Masami
    Takemura, Masahiko
    Adachi, Kazushige
    Wakimoto, Akinori
    Nishizaki, Takamichi
    Shiki, Yasuhiko
    Tsutsui, Tateki
    Kanda, Yuki
    Kobayashi, Eiji
    Hashimoto, Kae
    Mabuchi, Seiji
    Ueda, Yutaka
    Sawada, Kenjiro
    Tomimatsu, Takuji
    Kimura, Tadashi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (06) : 1239 - 1247
  • [37] Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study
    Keldsen, N
    Havsteen, H
    Vergote, I
    Bertelsen, K
    Jakobsen, A
    GYNECOLOGIC ONCOLOGY, 2003, 88 (02) : 118 - 122
  • [38] Gemcitabine and Epirubicin in platinum-resistant or refractory advanced ovarian cancer patients: Preliminary results of a phase II study
    Arcuri, C.
    Sorio, R.
    Scalone, S.
    Caffo, O.
    Griso, C.
    Merlin, F.
    Lucenti, A.
    Valduga, F.
    Frisinghelli, M.
    Arisi, E.
    Galligioni, E.
    ANNALS OF ONCOLOGY, 2005, 16 : 80 - 80
  • [39] Clinical Trials of Palliative Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: Time to Think Differently?
    Friedlander, Michael L.
    Stockler, Martin Richard
    Butow, Phyllis
    King, Madeleine Trudy
    McAlpine, Jessica
    Tinker, Anna
    Ledermann, Jonathan A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18) : 2362 - 2362
  • [40] Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial
    Gaillard, S.
    Oaknin, A.
    Ray-Coquard, I. L.
    Vergote, I. B.
    Scambia, G.
    Colombo, N.
    Ghamande, S. A.
    Soto-Matos, A.
    Fernandez, C. M.
    Kahatt, C.
    Gomez, J.
    Nieto, A.
    Torres, N.
    Pardo-Burdalo, B.
    Papai, Z.
    Kristeleit, R. S.
    O'Malley, D. M.
    Benjamin, I.
    Pautier, P.
    Lorusso, D.
    ANNALS OF ONCOLOGY, 2018, 29 : 332 - 332
12345